Clinical Trial Detail

NCT ID NCT02016729
Title A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Amgen
Indications

acute myeloid leukemia

Therapies

Trametinib

AMG 232

Age Groups: adult

No variant requirements are available.